Kiniksa Pharmaceuticals International, plc (KNSA) Stock Overview
Explore Kiniksa Pharmaceuticals International, plc’s financial performance, market position, analyst ratings, and future outlook.
Kiniksa Pharmaceuticals International, plc (KNSA)
Key Financials
Key Financials
Market Cap
7.5B
P/E Ratio
66.50
EPS (TTM)
$1.30
ROE
0.17%
KNSA Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Kiniksa Pharmaceuticals International, plc (NASDAQ: KNSA) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Kiniksa Pharmaceuticals International, plc's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of KNSA on the NASDAQ shows an RSI of 59.56, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $83.80 for the NASDAQ listing.
Key metrics behind Kiniksa Pharmaceuticals International, plc's NASDAQ-traded stock include a P/E ratio of 66.50 and a market capitalization of 7.5B. Combined with our AI analysis, these give both institutional and retail investors a clear view of KNSA on the NASDAQ.